CA2319782A1 - Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome - Google Patents
Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome Download PDFInfo
- Publication number
- CA2319782A1 CA2319782A1 CA002319782A CA2319782A CA2319782A1 CA 2319782 A1 CA2319782 A1 CA 2319782A1 CA 002319782 A CA002319782 A CA 002319782A CA 2319782 A CA2319782 A CA 2319782A CA 2319782 A1 CA2319782 A1 CA 2319782A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- complex
- derivative
- glut1
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4736—Retinoblastoma protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des complexes de la protéine du rétinoblastome (RB) avec des protéines identifiées comme interagissant avec RB par un système amélioré de criblage à deux hybrides de levures modifiés. Les protéines identifiées comme devant interagir avec RB sont RN-tre, CAS, IP-30, L6, IK, LDH-B, Nlk1(Nek 2), cyclophiline A, Zap 3, CD24*, Set*, GluT1* et 115392*. Ainsi, l'invention présente concerne des complexes de RB et de RN-tre, CAS, IP-30, L6, IK, LDH-B, Nlk1(Nek 2), la cyclophiline A, Zap 3, CD24*, Set*, GluT1* et 115392* ainsi que des dérivés, fragments et analogues desdits composés. L'invention concerne également les gènes et protéines CD24*, Set*, GluT1* et 115392* ainsi que des dérivés, fragments et analogues de ces composés. L'invention a également trait à des techniques de criblage de complexes visant à améliorer l'efficacité du traitement et/ou de la prévention de certaines maladies et troubles, notamment de pathologies hyperprolifératives dont le cancer, les maladies neurodégénératives et les maladies virales.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7455998P | 1998-02-12 | 1998-02-12 | |
US60/074,559 | 1998-02-12 | ||
US24896099A | 1999-02-11 | 1999-02-11 | |
US09/248,960 | 1999-02-11 | ||
PCT/US1999/003072 WO1999041376A2 (fr) | 1998-02-12 | 1999-02-12 | Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2319782A1 true CA2319782A1 (fr) | 1999-08-19 |
Family
ID=26755794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002319782A Abandoned CA2319782A1 (fr) | 1998-02-12 | 1999-02-12 | Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1054969A2 (fr) |
JP (1) | JP2002503466A (fr) |
CA (1) | CA2319782A1 (fr) |
WO (1) | WO1999041376A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6476193B1 (en) * | 1998-10-06 | 2002-11-05 | Curagen Corporation | NLK1 protein and NLK1 protein complexes |
WO2004014301A2 (fr) * | 2002-08-07 | 2004-02-19 | Exelixis, Inc. | Genes psmc utilises comme modificateurs du trajet retiniblastome (rb) et techniques d'utilisation |
WO2004048541A2 (fr) * | 2002-11-25 | 2004-06-10 | Exelixis, Inc. | Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants |
CA2669520C (fr) | 2006-11-13 | 2016-07-26 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Procedes de traitement d'un cancer a l'aide de molecules d'arnic dirigees contre cd24 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071715A (en) * | 1993-08-12 | 2000-06-06 | Board Of Regents, The University Of Texas System | Nucleic acids encoding novel proteins which bind to retinoblastoma protein |
EP0685493A1 (fr) * | 1994-06-01 | 1995-12-06 | CANJI, Inc. | Protéines de fusion suppresseurs de tumeurs |
WO1998021228A1 (fr) * | 1996-11-15 | 1998-05-22 | Canji, Inc. | Expression specifique tissulaire de la proteine du retinoblastome |
-
1999
- 1999-02-10 EP EP99932509A patent/EP1054969A2/fr not_active Withdrawn
- 1999-02-12 JP JP2000531557A patent/JP2002503466A/ja not_active Withdrawn
- 1999-02-12 WO PCT/US1999/003072 patent/WO1999041376A2/fr not_active Application Discontinuation
- 1999-02-12 CA CA002319782A patent/CA2319782A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999041376A2 (fr) | 1999-08-19 |
JP2002503466A (ja) | 2002-02-05 |
EP1054969A2 (fr) | 2000-11-29 |
WO1999041376A3 (fr) | 2000-02-10 |
WO1999041376A9 (fr) | 2001-02-01 |
WO1999041376A8 (fr) | 2000-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6627405B1 (en) | 53BP2 complexes | |
AU4869399A (en) | Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon) | |
AU778692B2 (en) | NLK1 -interacting proteins | |
AU761651B2 (en) | CDK2 protein and CDK2 protein complexes | |
JP2002510490A (ja) | Lystタンパク質複合体およびlyst相互作用タンパク質 | |
EP1177286A1 (fr) | Proteine capable d'interaction avec un polypeptide mdm et procedes d'utilisation | |
AU770000B2 (en) | Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof | |
CA2319782A1 (fr) | Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome | |
AU4690499A (en) | Interaction of p27(kip1) with fkbp-12 | |
AU3291799A (en) | Retinoblastoma protein complexes and retinoblastoma interacting proteins | |
CA2349839C (fr) | Ucp5 | |
WO2002102987A2 (fr) | Methodes et compositions basees sur des interactions proteiques avec mastermind |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |